logo BDSP

Base documentaire

  1. Fulltext. The cost-effectiveness of HIV prevention targeting : How much more bang for the buck ?

    Article - En anglais



    Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified.


    This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention.


    The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations.

    Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted.


    Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.

    Mots-clés Pascal : Programme sanitaire, Prévention, SIDA, Virose, Infection, Ciblage, Risque élevé, Analyse coût efficacité, Economie santé, Homme, Evaluation, Immunopathologie, Immunodéficit, Population cible

    Mots-clés Pascal anglais : Sanitary program, Prevention, AIDS, Viral disease, Infection, Targeting, High risk, Cost efficiency analysis, Health economy, Human, Evaluation, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0152659

    Code Inist : 002B30A01C. Création : 21/05/1997.